{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T07:13:20Z","timestamp":1769843600376,"version":"3.49.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.clindermatol.2017.10.014","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T02:45:29Z","timestamp":1507171529000},"page":"231-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blistering diseases in the mature patient"],"prefix":"10.1016","volume":"36","author":[{"given":"Ines","family":"Lako\u0161 Juki\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Jerkovi\u0107 Gulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branka","family":"Marinovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2017.10.014_bb0005","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1529-8019.2003.01631.x","article-title":"Blistering disorders: diagnosis and treatment","volume":"16","author":"Yeh","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1024\/0040-5930\/a000080","article-title":"Bull\u00f6se autoimmundermatosen","volume":"67","author":"Hertl","year":"2010","journal-title":"Ther Umschau"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0015","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40266-016-0402-1","article-title":"Autoimmune blistering diseases in the elderly: clinical presentations and management","volume":"33","author":"Kim","year":"2016","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.7241\/ourd.20134.159","article-title":"Autoimmune basement membrane and subepidermal blistering diseases","volume":"4","author":"Maria","year":"2013","journal-title":"Our Dermatol Online"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjd.14408","article-title":"Laboratory diagnosis of pemphigus: direct immunofluorescence remains the gold standard","volume":"175","author":"Giurdanella","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0030","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.clindermatol.2011.01.008","article-title":"Significance of immunofluorescence in the diagnosis of autoimmune bullous dermatoses","volume":"29","author":"Jukic","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clindermatol.2010.07.010","article-title":"Autoimmune blistering diseases in the elderly","volume":"29","author":"Parker","year":"2011","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0040","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1471-2407-4-94","article-title":"An electronic application for rapidly calculating Charlson comorbidity score","volume":"4","author":"Hall","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0045","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2165\/00002512-200421120-00002","article-title":"Management of autoimmune skin disorders in the elderly","volume":"21","author":"Loo","year":"2004","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2133.1990.tb16127.x","article-title":"Structural changes in ageing skin","volume":"122","author":"Montagna","year":"1990","journal-title":"Br J Dermatol"},{"issue":"suppl 3","key":"10.1016\/j.clindermatol.2017.10.014_bb0055","first-page":"8C","article-title":"The effects of ultraviolet exposure on skin melanin pigmentation","volume":"18","author":"Ortonne","year":"1990","journal-title":"J Int Med Res"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0060","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/wound.2011.0356","article-title":"Characteristics of the aging skin","volume":"2","author":"Farage","year":"2013","journal-title":"Adv Wound Care"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0065","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.micron.2003.11.005","article-title":"Skin aging and natural photoprotection","volume":"35","author":"Wulf","year":"2004","journal-title":"Micron"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2165\/00128071-200910020-00001","article-title":"Clinical implications of aging skin: cutaneous disorders in the elderly","volume":"10","author":"Farage","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0075","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0080","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0190-9622(99)70061-7","article-title":"Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence","volume":"41","author":"Jung","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0095","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1111\/j.1365-4632.2004.02292.x","article-title":"Spectrum of autoimmune bullous diseases in Kuwait","volume":"43","author":"Nanda","year":"2004","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0100","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0105","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.det.2011.07.003","article-title":"Autoimmune blistering diseases: incidence and treatment in Croatia","volume":"29","author":"Marinovic","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0110","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0115","first-page":"844","article-title":"Autoimmune bullous skin diseases. Part 1: Clinical manifestations","volume":"9","author":"Kneisel","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0120","doi-asserted-by":"crossref","first-page":"A379","DOI":"10.1016\/j.autrev.2009.10.009","article-title":"Geoepidemiologic considerations of auto-immune pemphigus","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0125","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/1346-8138.12675","article-title":"Cooperative Group on Fogo Selvagem Research. Update on fogo selvagem, an endemic form of pemphigus foliaceus","volume":"42","author":"Aoki","year":"2015","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0130","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0190-9622(88)70236-4","article-title":"Chronic bullous disease of childhood, childhood cicatricial pemphigoid, and linear IgA disease of adults. A comparative study demonstrating clinical and immunopathologic overlap","volume":"19","author":"Wojnarowska","year":"1988","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.clindermatol.2011.03.008","article-title":"Linear immunoglobulin A bullous dermatosis","volume":"30","author":"Fortuna","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0140","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.annder.2011.01.010","article-title":"Dermatose \u00e0 IgA lin\u00e9aire: revue de la litt\u00e9rature","volume":"138","author":"Ingen-Housz-Oro","year":"2011","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0145","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/ajg.2014.55","article-title":"Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study","volume":"109","author":"West","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0150","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2133.2011.10385.x","article-title":"Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland","volume":"165","author":"Salmi","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0155","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1590\/S0365-05962010000400010","article-title":"Imunofluoresc\u00eancia direta e indireta","volume":"85","author":"Aoki","year":"2010","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0160","first-page":"CD002292","article-title":"Interventions for bullous pemphigoid","author":"Kirtschig","year":"2010"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0165","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1365-2133.2012.11108.x","article-title":"Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort","volume":"167","author":"della Torre","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0170","first-page":"399","article-title":"The diagnosis and treatment of autoimmune blistering skin diseases","volume":"108","author":"Schmidt","year":"2011","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0175","first-page":"E19","article-title":"Development of bullous pemphigoid in a patient with psoriasis and metabolic syndrome","volume":"98","author":"Lesniewska","year":"2016","journal-title":"Cutis"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0180","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0923-1811(94)00371-K","article-title":"The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan","volume":"9","author":"Ogawa","year":"1995","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0185","doi-asserted-by":"crossref","first-page":"37125","DOI":"10.1038\/srep37125","article-title":"Psychiatric and neurological disorders are associated with bullous pemphigoid\u2014a nationwide Finnish Care Register study","volume":"6","author":"F\u00f6rsti","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0190-9622(80)80247-7","article-title":"Internal disorders associated with bullous disease of the skin. A critical review","volume":"3","author":"Callen","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0195","first-page":"42","article-title":"The incidence of internal malignancies in autoimmune bullous diseases","volume":"32","author":"Iwashita","year":"2007","journal-title":"Tokai J Exp Clin Med"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0200","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0205","first-page":"833","article-title":"S2k guidelines for the treatment of pemphigus vulgaris\/foliaceus and bullous pemphigoid","volume":"13","author":"Eming","year":"2015","journal-title":"JDDG J der Dtsch Dermatologischen Gesellschaft"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0215","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/bjd.13717","article-title":"Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology","volume":"172","author":"Feliciani","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0220","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.det.2011.06.003","article-title":"Evidence-based management of bullous pemphigoid","volume":"29","author":"Daniel","year":"2011","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0225","first-page":"925","article-title":"Treatment of bullous pemphigoid with prednisolone only: 0.75 mg\/kg\/day versus 1.25 mg\/kg\/day. A multicenter randomized study","volume":"111","author":"Morel","year":"1984","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0230","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1346-8138.2010.00920.x","article-title":"Tetracycline and niacinamide control bullous pemphigoid but not pemphigus foliaceus when these conditions coexist","volume":"37","author":"Shioara","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0235","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0240","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12378","article-title":"Topical high potency steroid proclaimed optimal therapy for bullous pemphigoid in the elderly","volume":"30","author":"Schwartz","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0245","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3109\/08916934.2011.606452","article-title":"Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update","volume":"45","author":"Czernik","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0250","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0255","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0260","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/archderm.138.3.370","article-title":"The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators","volume":"138","author":"Chan","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0265","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.survophthal.2015.12.007","article-title":"Update on ocular cicatricial pemphigoid and emerging treatments","volume":"61","author":"Queisi","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0270","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/S0140-6736(00)04971-0","article-title":"Anti-epiligrin cicatricial pemphigoid and relative risk for cancer","volume":"357","author":"Egan","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0275","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0280","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jaad.2012.10.018","article-title":"Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature","volume":"68","author":"Shetty","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0285","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0290","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/08916934.2011.606450","article-title":"Epidermolysis bullosa acquisita: autoimmunity to anchoring fibril collagen","volume":"45","author":"Chen","year":"2012","journal-title":"Autoimmunity"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0295","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clindermatol.2011.03.011","article-title":"Epidermolysis bullosa acquisita","volume":"30","author":"Gupta","year":"2012","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/812029","article-title":"Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita","volume":"2013","author":"Ludwig","year":"2013","journal-title":"ISRN Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0305","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/14656566.2011.549127","article-title":"Current concepts in the treatment of epidermolysis bullosa acquisita","volume":"12","author":"G\u00fcrcan","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0310","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2340\/00015555-1065","article-title":"Epidermolysis bullosa acquisita: a retrospective clinical analysis of 30 cases","volume":"91","author":"Kim","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0315","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1346-8138.2009.00799.x","article-title":"Epidermolysis bullosa acquisita: what\u2019s new?","volume":"37","author":"Ishii","year":"2010","journal-title":"J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0320","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2006.07596.x","article-title":"A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita","volume":"156","author":"Crichlow","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/archderm.142.2.147","article-title":"Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab","volume":"142","author":"Schmidt","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0330","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2133.2007.08048.x","article-title":"Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab","volume":"157","author":"Sadler","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0335","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40257-016-0235-z","article-title":"Paraneoplastic pemphigus and autoimmune blistering diseases associated with neoplasm: characteristics, diagnosis, associated neoplasms, proposed pathogenesis, treatment","volume":"18","author":"Kartan","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0340","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/bjd.15389","article-title":"Paraneoplastic pemphigus associated with Castleman disease: progression from mucous to mucocutaneous lesions with epitope-spreading phenomena","volume":"176","author":"Okahashi","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0345","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00432-010-0874-z","article-title":"Improved outcomes after complete resection of underlying tumors for patients with paraneoplastic pemphigus: a single-center experience of 22 cases","volume":"137","author":"Zhang","year":"2011","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0350","first-page":"269","article-title":"Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20(+) follicular lymphoma-associated paraneoplastic pemphigus","volume":"137","author":"Borradori","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0355","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/bjd.12324","article-title":"Alemtuzumab is effective against severe chronic lymphocytic leukaemia-associated paraneoplastic pemphigus","volume":"169","author":"Bech","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0360","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-0960.2012.00921.x","article-title":"Paraneoplastic pemphigus","volume":"54","author":"Yong","year":"2013","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0365","first-page":"1861","article-title":"Autoimmune bullous dermatoses: a review","volume":"65","author":"Bickle","year":"2002","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0370","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1001\/archderm.1979.04010040006002","article-title":"Correlation of antibodies in skin and serum with disease severity in pemphigus","volume":"115","author":"Judd","year":"1979","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0375","first-page":"364","article-title":"The autoimmune bullous diseases","volume":"31","author":"Wakelin","year":"1997","journal-title":"J R Coll Physicians Lond"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0380","unstructured":"Aggarwal RR, Gupta S, Garg RK. Pemphigus foliaceus. Indian J Dermatol Venereol Leprol.1979; 45:301-302."},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/07853890.2016.1222450","article-title":"Dermatitis herpetiformis: a cutaneous manifestation of coeliac disease","volume":"49","author":"Collin","year":"2017","journal-title":"Ann Med"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0390","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3109\/07853899809002482","article-title":"Dermatitis herpetiformis: coeliac disease of the skin","volume":"30","author":"Reunala","year":"1998","journal-title":"Ann Med"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0395","doi-asserted-by":"crossref","first-page":"914162","DOI":"10.1155\/2012\/914162","article-title":"Recent advances in dermatitis herpetiformis","volume":"2012","author":"Nakajima","year":"2012","journal-title":"Clin Dev Immunol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0400","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2133.2005.06345.x","article-title":"Lymphoma in patients with dermatitis herpetiformis and their first-degree relatives","volume":"152","author":"Hervonen","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0405","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/j.1365-2036.2012.04998.x","article-title":"The long-term risk of malignancy following a diagnosis of coeliac disease or dermatitis herpetiformis: a cohort study","volume":"35","author":"Grainge","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0410","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1590\/abd1806-4841.20131775","article-title":"Review: dermatitis herpetiformis","volume":"88","author":"Mendes","year":"2013","journal-title":"An Bras Dermatol"},{"key":"10.1016\/j.clindermatol.2017.10.014_bb0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1440-0960.2005.00152.x","article-title":"Sulfasalazine and dermatitis herpetiformis","volume":"46","author":"Willsteed","year":"2005","journal-title":"Australas J Dermatol"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X17302043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X17302043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:26:05Z","timestamp":1535329565000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X17302043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":83,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0738081X17302043"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2017.10.014","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blistering diseases in the mature patient","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2017.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}